MULTI-SECTORAL NATIONAL ACTION PLAN ON ANTIMICROBIAL RESISTANCE MONGOLIA, 2022-2025

JOINT ORDER OF THE MINISTER OF HEALTH AND MINISTER OF FOOD AGRICULTURE, LIGTH INDUSTRY

Date: May 02, 2022

Number A/255, A/137

Ulaanbaatar city

Approval of action plan

The joint order is issued based on the Clause 2 of the Article 24 of the Law on Government and Government action plan for 2020-2024 approved by the Government resolution N 203 in 2020.

- 1. Approve the "Multi-sectoral national action plan on antimicrobial resistance for 2022-2025.
- 2. Assign the Medicine and Medical Devices Regulatory Agency (D. Narantuya) and General Authority for Veterinary Medicine Services (D.Batchuluun) to ensure implementation of the national action plan and establish multi-sectoral national committee to monitor, discuss implementation results every half year and inform to Government ministries.
- 3. Assign the State Secretary of Ministry of Health (Ts. Erdembileg) and State Secretary of Ministry of Food, Agriculture and Light Industry (T. Jambaltseren) to monitor implementation of the multi-sectorial national action on AMR.
- 4. Assign all directors, heads of the health and food, agriculture and light industry organizations to estimate and plan annual budget for implementation of the national plan at organization's level.

| MINISTER OF HEALTH | MINISTER OF FOOD, AGRICULTURE, LIGHT INDUSTRY |
|--------------------|---|
| | MENDSAIKHAN 7 |

S. ENKHBOLD

MENDSAIKHAN.Z

Contents

| Abbreviations | 4 |
|---|----------------|
| Background | 7 |
| Rationale to develop the strategy | 7 |
| Prevalence of antibiotic consumption in Mongolia | 9 |
| Prevalence of AMR in Mongolia | 90 |
| Purpose of the strategy Errore. Il segnalibro no | on è definito. |
| Strategic objectives | 10 |
| Expected outcomes | 111 |
| Budget required for the implementation of the NAP: results of the cost a | nd budget |
| estimation exercise | |
| Monitoring and evaluation | 133 |
| References | 144 |
| Planned activities of the multi-sectoral national action plan on AMR (202 | 2-2025)16 |

Abbreviations

| AMR | Antimicrobial Resistance |
|------------|--|
| ATC | Anatomic Therapeutic Class |
| AWaRE | Access, Watch and Reserve |
| COVID-19 | Corona Virus Disease of 2019 |
| DDD | Daily Defined Dose |
| DID | Daily Defined Dose per 1000 Inhabitants |
| FAO | Food and Agriculture Organization |
| GAP | Global Action Plan |
| GASI | Government Agency for Specialized Inspection |
| GAVS | General Authority for Veterinary Services |
| GDHI | General Department for Health Insurance |
| GLASS | Global Antimicrobial Resistance and Antibiotic Use |
| IVM | Institute for Veterinary Medicine |
| MMRA | Medicines and Medical Devices Regulatory Agency |
| MNUMS | Mongolian National University of Medical Sciences |
| MULS | Mongolian University of Life Sciences |
| MoFALI | Ministry of Food, Agriculture and Light Industry |
| MoES | Ministry of Education and Science |
| MoET | Ministry of Environment and Tourism |
| MoF | Ministry of Finance |
| МоН | Ministry of Health |
| NAP | Multi-sectoral national action plan on AMR |
| NCCD | National Center for Communicable Diseases |
| NCHD | National Center for Health Development |
| NCPH | National Center for Public Health |
| NCZD | National Center for Zoonotic Diseases |
| NGO | Non-government organization |
| SRLFM | State Reference Laboratory for Food and Medicine |
| OIE | World Organization for Animal Health Over -The- Counter |
| OTC PPI | Plant Protection Institute |
| SCVL | State Central Veterinary Laboratory |
| SDG | Sustainable Development Goals |
| SLVMTC | State Laboratory for Veterinary Medicine Testing and Certification |
| | United Nations |
| WAAW | World Antibiotic Awareness Week |
| WAAW | World Health Organization |
| | |

Background

Antimicrobial resistance (AMR) is a major problem that affects our ability to treat infections in all countries and all people. Resistant organisms can easily spread through human and animal migration, food or water, and resistant genes can be transferred from one species to another, without any consideration about one's wealth or status or any geographical or ecological restrictions. Therefore, countries should coordinate and control AMR across all stakeholders, including governments, international organizations, private entities, investors and individuals.

Internationally, substantial guidance and tools for containing and combating AMR are available. In 2015, the Global Action Plan on Antimicrobial Resistance (GAP) was endorsed by the Member States of the World Health Organization (WHO), Food and Agriculture Organization (FAO) and World Organization for Animal Health (OIE) in 2015.(1) The GAP included 5 strategic objectives offering a framework for national action plans to combat and contain AMR in the subsequent period of 10 –years.(1)

The GAP was then reaffirmed as a blueprint for tackling AMR during the 71st session of the UN General Assembly, where 193 Heads of State adopted resolution A/RES/71/3, which included a high-level political declaration committing countries to support and implement the GAP at national, regional and global levels. Following the GAP, AMR was encompassed within the Sustainable Development Goals (SDGs) as Framework for Action in 2016.(2)

The WHO performed a global surveillance of AMR, identifying key challenges in Member States. The identified challenges include a lack of comprehensive strategy to combat AMR in countries, unjustified use of antibiotics, lack of national and regional control mechanism to detect and control AMR, as well as insufficient actions to undertake when AMR is detected.(3)

As of today, more than 80% of the antibiotics in the veterinary sector is used for non-medical purpose; instead it is used as breed-mix for animal growth purposes, which in turn increases the risk of food-borne antibiotic resistance in humans. The FAO reports on antibiotics used in the veterinary sector also indicate that the use of antibiotics will increase by almost 40% to 105.6 tonnes by 2030, when compared to 2010.(4)

Inappropriate use of antimicrobials may lead to development of antimicrobial resistance. Consequences of AMR include negative outcomes on individual, organizational as well as economic level. Negative outcomes on the individual level may include prolonged treatment effects, development of adverse events and potentially increased mortality. For health organizations, the prevalence of AMR may lead to difficulties to provide treatment for infectious diseases, limited to no choice of treatment alternatives, increased treatment cost. Therefore patients, health care professionals and the countries should work together and responsively to assure the quality and responsible use of antimicrobials at all times. On the other hand, no new antimicrobials were developed in the pipeline for the last 30 years. This means that the choice of available treatment is very limited with increased antimicrobial resistance to current medicines.

Non-communicable diseases, including cancer, diabetes, injuries were the main cause for mortality in 2018, whereas the multi-drug resistance or super-bacteria will most likely take this place, the estimates show that up to one million residents will likely to die due to the development of super-bugs.(5) Globally, AMR infections are estimated to cause 700,000 deaths each year. If no action is taken, this figure is predicted to rise to 10 million, alongside a cumulative cost of \$100 trillion, by 2050.(6) AMR also threatens many of the SDGs.(6) The World Bank estimates that 28 million people will be forced into extreme poverty additionally in less than 30 years unless AMR is contained.(7)

The WHO Assembly on AMR also emphasized the collaborative approach to be undertaken in the midst of the fight against AMR and endorsing a concerted "One Health" approach — which linked various sectors and actors in defence of human, animal and environmental health. They also agreed to mobilize adequate, predictable and sustained resources to implement those programmes and pledged to raise awareness of the phenomenon around the world.(8, 9)

The WHO/FAO/OIE tripartite survey of stakeholders involved in the assessment of the NAP indicated that the developing and implementation strategies should be focused on One-health approach and include all stakeholders in the human, animal as well as food sectors. (8, 9) (10)

Rationale to develop the strategy

The GAP sets out five strategic objectives: (1) to improve awareness and understanding of antimicrobial resistance; (2) to strengthen knowledge through surveillance and research; (3) to reduce the incidence of infection; (4) to optimize the use of antimicrobial agents; and (5) to ensure sustainable investment in countering antimicrobial resistance. These objectives can be attained through the implementation of clearly identified actions by Member States, therefore, it is expected that countries will develop their own national action plans on antimicrobial resistance in line with the global plan.

Programs to improve appropriate use of antimicrobials have been implemented in Mongolia since 2013. The Animal Health Law which was adopted by the Parliament in 2017has played an important step towards compliance with international standards and a precondition for increased exports of livestock products. Also, it served as one of the major rudiments towards developing the 1st multi-sectoral national action plan to combat the AMR in Mongolia (12) which was approved jointly by the Health Minister and Minister for Food and Light Industry reinforced in 2017. (13)

Mongolian 1st National Action Plan (2017-2020): Re-Cap

The 1st Mongolian national action plan to combat AMR (2017-2020) was developed and approved the Government in 2017. The goal of the National Action Plan was to promote rational use of antibiotics and prevention from the emergence and spread of AMR, improve surveillance of AMR and diagnostics, treatment of antimicrobial infections and enhance quality of hospital care. It consisted of six components.

- Establish a governance mechanism and ensure multisectoral role to combat antimicrobial resistance, sustainable investment and functioning
- > Strengthen surveillance and diagnostic capacity for AMR and research
- > Reduce spread of infections through better infection prevention and control
- > Ensure quality and safety of antimicrobial medicines
- > Optimize use of antimicrobials in the human and animal sectors
- Raise awareness and understanding of AMR and rational use of the general public, herdsmen and health professionals.

The implementation of the 1st multi-sectoral national action plan was assessed in a recent review.(14) The 1st NAP included a total of 69 activities within the six components. Of those activities, almost 60% were successfully implemented (n= 40,

58%), one-third were assessed as half-completed (20, 29%), and 9 activities were not achieved (13%). Overall, the implementation status of the NAP was 87%. A number of challenges caused a delay in the implementation the strategy, more specifically activities specified in the veterinary sector were not executed, mostly due to the ongoing COVID-19 restrictions.(14) The challenges and causes of delayed implementation have been briefly described in this rapid review and reflected to continue their implementation in the next multi-sectoral national action plan on AMR.

Prevalence of antibiotic consumption in Mongolia

Published studies regarding the antibiotic consumption include the WHO supported surveillance study on antibiotic consumption. The study employed import and manufactured data to provide estimates with WHO standardized methodology. The Daily Defined Dose per 1000 inhabitants (DID) indicated it was the highest in 2015 among the Western Pacific Countries (15, 16), although a later repeat study in 2019 indicated a decrease by 21.3% (DID=37) (15).

A 5-year hospital level data on used antibiotics were reported in 2020.(17) The DDD/100 beds was 199-420, much higher than those findings reported from similar settings in other countries. Overall, the consumption of antibiotics is still excessive(18), urging the Government to undertake substantial actions.

As of November 2021, there were 4243 medicines registered, of which 11% (n=471) were antibiotics. Most of registered antibiotics were imported (n=440), and approximately 7% were locally manufactured.(19) Analysis of reimbursed medicines from the Health Insurance General Agency indicated the most dispensed medicines belonged to amoxicillin (38.8%). The dispensed cohort involved patients aged 0 to 19 years (20). Although amoxicillin was the most prevalent dispensed medicine, the recent data shows that the proportion of macrolides, fluroquinolones and carbapenems increased, potentially due to global pandemic situation.(20) These are antibiotic classes belong to the 'Watch' group that have higher resistance potential and should be prioritized as key targets of stewardship programs and monitoring.(21)

In 2021, a national-wide study was executed by the Medicines and Medical Devices Regulatory Authority of Mongolia.(22) The study assessed the knowledge, attitude and practice towards antimicrobial resistance and appropriate use of antimicrobial medicines in the community and health professionals. The study reported that the community members have inconsistent source of information regarding the appropriate use of medicines, depending on their residency. Moreover, the doctors indicated the long waiting time for sensitivity analysis as one of the major challenges when prescribing antibiotics. Among the respondents, only one- third had sufficient knowledge, one in five respondents had appropriate attitude towards antimicrobials and AMR(22).

Prevalence of AMR in Mongolia

Data regarding antimicrobial resistance are insufficient in Mongolia. Previous reports from two tertiary hospitals in Mongolia demonstrated that only one in five infections, microbiological diagnostics (19%) were done, with antibiotics were given without sensitivity testing in 92% of cases.(23)

Increasing rates of MRSA confirmed cases were reported from Mongolian hospitals. Data from 4 major hospitals of Ulaanbaatar showed 3% MRSA in 207 *Staphylococcus aureus* strains investigated.(24) A 2013 study reported that among 251 *Staphylococcus aureus* isolates, methicillin resistance was confirmed in 8.8% of isolates (22/251)(25)

A 2021 study investigated the rate of gram-negative multi-drug resistant organism in admitted and hospitalized patients in Mongolia. Of 158 eligible patients, baseline colonization rate was found in almost 30% (n=46). After hospitalization, this rate increased up to 70(p<0.01). Enterobacterales were found to be the predominant colonizer and was highly resistant to 3^{rd} generation cephalosporin, particularly cefotaxime.(26)

Increased use of cefotaxime was found in two hospitals of Mongolia(11.1–13.1 DDD/100 bed days and 4.2–15.7 DDD/ 100 bed days).(17) This reiterates the high risk of hospital-acquired infection being posed to inpatients and the need for strengthening the infection control in the hospitals.(26)

In farm animals, particularly chicken, resistant bacteria to Campylobacter species were detected in Ulaanbaatar area. The study reported that all isolates were resistant to tetracycline, and 3 Campylobacter coli isolates were resistant to erythromycin.(27)

Considering high antibiotic use, documentation of prevalent AMR in both human and animal isolates, it is important to control and monitor the consumption of antimicrobials and AMR in Mongolia. In particular, evidence-based data regarding the AMR need to be generated at the national level. Moreover, the data must be analysed and distributed to relevant authorities to inform the practice, as well as the policymakers.

Existing efforts and future actions must are directed to strengthen surveillance system for resistant pathogens, prevent the spread of infection and share and exchange findings with international organizations and other countries.

Amongst others, the key activities to prioritize are stop the over-the-counter (OTC) availability of antimicrobials from community pharmacies, strengthening control of reimbursed antimicrobials via electronic prescription and dispensing system (triage linkage between the prescriber, dispenser, health insurance claims, and the patient), intensified actions towards improving the knowledge and attitude on AMR among public, especially among herders and those residing in remote areas.

Purpose of the strategy

The Multi-sectoral national action plan on antimicrobial resistance aims to prevent and tackle antimicrobial resistance through improving surveillance in human and animal health sectors, controlling the consumption, strengthening infection prevention control, and increasing knowledge and attitude of public, human and animal health professionals to optimize use of antimicrobials.

Strategic objectives

1. Strengthen the governance mechanism to prevent from AMR, establish a multisectoral coordination committee which will develop and monitor annual action plan and its implementation.

2. Improve the detection and surveillance of antimicrobial resistance, strengthen capacity to collate, analyze and inform data on antimicrobial resistance at national level.

3. Strengthen responsible use of antimicrobials by controlling antimicrobial consumption, reducing irrational use of antimicrobials, and implementing effective stewardship programs.

4. Improve infection prevention and control, undertake preventive measures from environmental contamination, stop the spread of infection.

5. Raise awareness of antimicrobials among community, professionals, incorporate the training modules in high school curricula, improve knowledge and practice to prevent and reduce antimicrobial resistance.

Expected outcomes

| Strategic objectve | Current baseline | Expected outcomes |
|---|---|---|
| Governance | No fully functioning committee | Established multi-sectoral committee, organized committee meeting at least twice a year |
| Surveillance, prevention | No baseline study | Generated, analyzed national data linked with GLASS. |
| Consumption of antimicrobials | DID 37 according to imported and manufactured data, started estimation using health insurance data No baseline data available in the veterinary sector | DID decreased by 10% (DID 27) Completed estimation using health insurance data based on the WHO ATC/DDD methodology with report by AWARE classification. |
| Infection prevention control and surveillance | No baseline data | Information available on hospital-acquired infection |
| Information, education, advocacy | Advocacy and trainings for WAAW AMR integrated into the postgraduate training curriculum | At least 5 main activities organized every year for the celebration of WAAW Integrated AMR modules to secondary and high school curricula, and in agriculture sector's training programs. |

Budget required for the implementation of the NAP: results of the cost and budget estimation exercise

The required budget to implement detailed activities was estimated using the WHO-NAP- budgeting tool. The estimates include inflation rates for the year 2023, 2024 and 2025, respectively(28). At the time of writing the report, 3000.2 MNT was equal to 1 USD. The local UN tariffs applicable for individual organizations and activities were used to calculate the estimates, unless otherwise specified.

The required 4-year budget for the implementation of the NAP was estimated to be 13,914,468,019.12 MNT. Most (70%) of the budget will be spent for the activities classified in the 'infection prevention control' strategic area for both human and veterinary sectors. Activities planned under this strategic objective included procurement of equipment and tools required for sanitation and disinfection, as well as consumables, infrastructure repairs, maintenance required for infection control and monitoring.

Activities relating to governance and coordination require more than 12% of the planned budget in 2022, whereas the estimated budget decreases by one-third in the following years of the NAP implementation. Approximately 15% of the planned budget is directed to implement activities in the area of strengthening surveillance, generating evidence-based knowledge.



Figure 1 Proportion of allocated budget by strategic objective, by year

A small proportion of the funding is indicated as available or partially funded (**0.65**%, 90,179,787.46 MNT), mostly through the government and international donor organizations.

Table 1 Required budget overview and availability by strategic objective and year (in million tugriks)

| Strategic objectives | Edu | eness/ cation/ ining | | nance/ ination | Optimized Use | IPC | Evid | illance/ ence/ /ledge |
|-------------------------|------|----------------------------|-------|-------------------|------------------|---------|-------|-----------------------------|
| Funding availability | Yes | No | Yes | No | No | No | Yes | No |
| Doguirod hudgot | 0 | 92.74 | 12.5 | 338.24 | 6.38 | 2040.69 | 5.5 | 382.77 |
| Required budget in 2022 | 0 | 92.74 | 12.5 | JJ0.24 | 0.30 | 2040.68 | 5.5 | 302.11 |
| Required budget in 2023 | 1.34 | 233.33 | 14.37 | 142.64 | 6.2 | 2390.16 | 9.65 | 511.34 |
| Required budget in 2024 | 1.42 | 231.45 | 14.63 | 112.06 | 5.88 | 2679.8 | 10.21 | 602.26 |
| Required budget in 2025 | 0 | 189.57 | 15.69 | 147.5 | 6.3 | 3139.76 | 4.87 | 565.25 |

Monitoring and evaluation

The interim and final monitoring and evaluations will be performed jointly by the Ministry of health, ministry of food, agriculture and light industry involving relevant agencies and stakeholders.

References

1. World Health Organization. Global action plan on antimicrobial resistance. 2015.

2. Assembly UG. Political declaration of the high-level meeting of the general assembly on antimicrobial resistance. New York, NY: United Nations. 2016.

3. World Health Organization. Global surveillance of antibacterial resistance in humans: second WHO technical consultation. World Health Organization; 2014.

4. Food and Agriculture Organization. The FAO Action Plan on Antimicrobial Resistance 2021–2025. FAO Rome, Italty; 2021.

5. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022.

6. O'Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. The review on antimicrobial resistance. Review on Antimicrobial Resistance, London, United Kingdom. London, United Kingdom, <u>https://amr-review</u>. org/sites/default/files/AMR ...; 2014.

7. World Bank. Drug-resistant infections: a threat to our economic future: World Bank; 2017.

8. World Health Organization. Antimicrobial resistance: a manual for developing national action plans. 2016.

9. World Health Organization. Country progress in the implementation of the Global Action Plan on Antimicrobial Resistance: WHO, FAO and OIE global tripartite database. 2018.

10. World Health Organization. Strategic framework for collaboration on antimicrobial resistance: together for One health: Food & Agriculture Org.; 2022.

11. Монгол улс. Антибиотикийн зохистой хэрэглээг төлөвшүүлэх, эмэнд нянгийн тэсвэржилт үүсэхээс сэргийлэх стратеги /2013-2017/. 2013.

12. Монгол улс. Мал, амьтны эрүүл мэндийн тухай. 2018.

13. Монгол улс. Нянгийн тэсвэржилтээс сэргийлэх үйл ажиллагааны салбар дундын төлөвлөгөө /2017-2020/. 2017.

14. Ministry of Health. Rapid assessment of the implementation of National Action Plan to Combat Antimicrobial Resistance in Mongolia /2017-2020/. 2022.

15. Монгол улс, Эрүүл мэндийн яам. Антибиотик эмийн тандалт судалгаа 2019.

16. Dorj G, Dembereldorj B, Choijoo A, Enkhee E, Sanjjav T, Blix HS. National surveillance of antibiotic consumption in Mongolia. International Journal of Infectious Diseases. 2020;101:96.

17. Dorj G, Salvesen Blix H, Sunderland B, Gankhulug B, Tegshee O, Purevkhuu M, et al. Antibiotic utilization trends in two state hospitals of Mongolia from 2013 to 2017. BioMed Research International. 2019;2019.

18. World Health Organization. Antimicrobial consumption in the WHO Western Pacific Region: early implementation of the Western Pacific Regional Antimicrobial Consumption Surveillance System (WPRACSS). 2021.

19. Монгол улс, Эм эмнэлгийн хэрэгслэлийн зохицуулалт хяналтын газар. Монгол улсын эм зүйн салбарын үзүүлэлт. 2021.

20. Монгол улс, Эрүүл мэндийн даатгалын сан. Эрүүл мэндийн даатгалын сангаас хөнгөлттэй үнээр олгогдох эм. 2020.

21. World Health Organization. 2021 AWaRe classification. 2021.

22. Монгол улс, Эм эмнэлгийн хэрэгслэлийн зохицуулалт хяналтын газар. Иргэдийн эмийн зохистой хэрэглээний талаарх мэдлэг, чадвар, хандлагын судалгаа. 2021.

23. Ider B-E, Clements A, Adams J, Whitby M, Muugolog T. Prevalence of hospital-acquired infections and antibiotic use in two tertiary Mongolian hospitals. Journal of Hospital Infection. 2010;75(3):214-9.

24. Orth D, Grif K, Erdenechimeg L, Battogtokh C, Hosbayar T, Strommenger B, et al. Characterization of methicillin-resistant Staphylococcus aureus from Ulaanbaatar, Mongolia. European Journal of Clinical Microbiology and Infectious Diseases. 2006;25(2):104-7.

25. Nair R, Hanson BM, Kondratowicz K, Dorjpurev A, Davaadash B, Enkhtuya B, et al. Antimicrobial resistance and molecular epidemiology of Staphylococcus aureus from Ulaanbaatar, Mongolia. PeerJ. 2013;1:e176.

Baljin B, Gurjav U, Tulgaa K, Baldan G, Gunchin B, Sandag T, et al. High Acquisition Rate of Gram-Negative Multi-Drug Resistant Organism Colonization During Hospitalization: A Perspective from a High Endemic Setting. Infection and Drug Resistance. 2021;14:3919.
Byambajav Z, Bulgan E, Hirai Y, Nakayama M, Tanaka M, Nitta Y, et al. Research Note:

Antimicrobial resistance of Campylobacter species isolated from chickens near Ulaanbaatar city, Mongolia. Poultry Science. 2021;100(3):100916.

28. World Bank. Inflation, consumer prices (annual %). 2022.

Planned activities of the multi-sectoral national action plan on AMR (2022-2025)

| | | Year | · | | | | | | Collaborating organizations | | | |
|-----|---|------|------|------|------|---|---|--------------------------------------|--|--|--|--|
| No | Activity | 2022 | 2023 | 2024 | 2025 | Indicator | Outcome | Implementing agency | | | | |
| | Strategic objective 1: Strengthen the governance mechanism to prevent from AMR, establish a multi-sectoral coordination committee which will develop and monitor annual action plan and its implementation | | | | | | | | | | | |
| 1.1 | Establish a multi-sectoral coordination committee to ensure implementation, and monitoring of the NAP | + | + | + | + | The decision of the meeting | Biannual meetings shall be held at 7 least times, actions discussed. | MMRA, GAVS | MoH, MoFALI, WHO, FAO, MoE, MoET, Codex- national committee | | | |
| 1.2 | Present and discuss results of activities against AMR, use and consumption of antimicrobial drugs in in human and agriculture sector, provide recommendations and make decisions | + | + | + | + | The number of resolutions achieved in meetings. | Results on AMR and antimicrobial use will be presented at least 4 times | MMRA, GAVS | Human drug council, Veterinary drug council | | | |
| 1.3 | Include budget required to implement AMR activities in organizations annual financial plan | + | + | + | + | The required budget included in the financial plan. | Required budget to implement the activities will be included in the annual budget of the organizations | All implementing organizations | MoH, MoFALI | | | |
| 1.4 | Conduct external evaluation on NAP implementation | - | + | - | + | Number of external evaluations | Mid and final evaluations will be completed, recommendations and conclusions will be made. | Multi-sectoral committee | MoH, MoFALI, MMRA, GAVS, WHO, UN, FAO | | | |
| 1.5 | Organise national conferences on prevention and control of AMR | - | + | + | + | Number of organized conferences, and seminars | National conferences will be attended by at least 250 participants | Multi-sectoral committee | MoH, MoFALI, MMRA, GAVS, WHO, UN, FAO, /OIE/ | | | |

| 1.6 | Include AMR related indicators in the accreditation and performance evaluation indicators in human and veterinary organizations | - | + | + | + | Indicators included in the assessment | Guidelines on antimicrobials will be developed, laboratories will be linked to the WHONET. | MOH, NCHD, GAVS, MoFALI | Health organizations, MASM |
|------|---|----------|--------|----------|--------|---|---|-------------------------------------|--|
| 1.7 | Join international networks, movements combatting AMR to learn and exchange information | + | + | + | + | Number of conferences and meetings attended | At least 5 times to attend international conferences on AMR. | MoH, MoFALI, MMRA, GAVS, NCCD | WHO, UN, FAO, OIE |
| 1.8 | Translate codex standard on food –borne AMR, discuss it at MASM, technical committee and public to get approval | - | + | - | + | | 2 codex guidelines, 1 regulation of practice will be translated and approved. | MoFALI, UN, FAO | MASM, GAVS |
| 1.9 | Revise and update regulation for Drug Therapeutic Committee in relation to AMR | + | + | - | - | Number of approved regulations | Health Minister's Order will be approved. | MMRA | Health organizations |
| 1.10 | Conduct an assessment on AMR legal framework in the agriculture sector | - | + | - | | Report of the assessment and recommendation | Recommendations based on the assessment will be provided. | Multi-sectoral committee | MoH, MoFALI, GAVS, MoET, GASI, International organizations |
| | gic objective 2: Improve the dete al level | ection a | and su | ırveilla | ince o | f antimicrobial resistar | nce, strengthen capacity to colla | ate, analyze and ir | nform data on AMR at |
| 2.1 | Develop and revise regulations with focus on detection, surveillance of AMR and identify roles and functions of authorities and organizations, information and reporting | - | + | + | - | Number of approved regulations | 2 | NCCD, GAVS | MoH, MoFALI, MMRA, International organizations |
| 2.2 | Conduct lab based surveillance study on AMR in human and veterinary sectors | + | + | + | + | Number of studies | Recommendationand conclusion based on study results will be reported. | NCCD, GAVS | MNUMS, IVM, Human and veterinary health departments in aimag and city, International organizations |

| 2.3 | Develop and revise guidelines, SOPs in conducting and analysing sensitivity tests to detect AMR | - | + | - | - | Number of newly implemented analysis methods | Guidelines, SOPs will be approved | NCCD, GAVS | MNUMS, IVM, SCVL, SLVMTC |
|------|--|---|---|---|---|--|--|---|--|
| 2.4 | Investigate the possibility to link hospital e-system /HIS, LIS/ with WHONET and exchange information | + | + | - | - | Report of the study, recommendation | Recommendations on linking the programs to WHONET will be provided | MoH, NCHD, hospitals | |
| 2.5 | Conduct a situational analysis on capacity of AMR surveillance in food and agriculture laboratories using UN, FAO proposed methods 'ATLASS' | + | - | - | - | Report of the assessment | Assessment on capacity to detect AMR and conduct surveillance will be completed | GAVS, SCVL, IVM, SLVMTC, SRLFM, NCCD | MoFALI, UN, FAO |
| 2.6 | Conduct trainings for human and veterinary laboratories on linkage and data exchange with global surveillance systems (GLASS, WHONET), invite international consultants | - | + | + | - | Number of trainings, report of the consultant | Laboratory staff will be trained | МоН | MMRA, NCCD, NCZD, IVM, NCPH, human and veterinary laboratories |
| 2.7 | Build national capacity to collect, collate, analyse and report AMR data | - | + | + | + | Number of professionals involved in the training | At least once per year trainings will be organized and knowledge of the professionals will be improved | NCCD, GAVS | MoH, MoFALI, MMRA |
| 2.8 | Expand linkage of national laboratory system with WHONET, by enabling aimag, district laboratories in a stepwise manner | + | + | + | + | Number of health organizations linked to the system | Central hospital, specialized centres, aimag and district hospitals will be linked to WHONET. | NCCD | Aimag and district hospitals, WHO |
| 2.9 | Develop report on resistance and inform to health care organizations twice a year | + | + | + | + | Nature and prevalence of resistant microbes | At least 6 reports will be distributed to health organizations | NCCD | Health organizations |
| 2.10 | Undertake external quality evaluation for microbiology laboratories in human and veterinary sectors | + | + | + | + | Number of externally evaluated laboratories | External evaluation will be completed | NCCD, NCZD, GAVS | MoH, MoFALI, WHO, OIE |

| 2.11 | Strengthen capacity of the laboratory staff in quality assurance, management and standard methods to detect AMR and conduct sensitivity analysis | - | + | + | - | Number of trained staff | At least 50% of laboratory staff will be trained and their skills improved. | GAVS | MoH, MoFALI, Codex- national committee |
|------|---|---|-------|--------|---------|---|---|--------------------|--|
| 2.12 | Conduct surveillance studies to detect resistance rates of common pathogens causing disease in plants | + | - | + | - | Number of surveillance tests | Report of surveillance, recommendations distributed to relevant authorities | MoFALI | PPI, GASI |
| | egic objective 3: Strengthen responsible and the segmenting effective stewardship prog | | e use | of ant | timicro | bbials by controlling an | timicrobial consumption, reduc | ing irrational use | of antimicrobials, and |
| 3.1 | Estimate consumption of antimicrobials used in veterinary by OIE method and develop reports | + | + | + | + | Number and classification of antimicrobials used in the veterinary sector | Reports will be distributed to national and international organizations | GAVS | MoH, MoFALI |
| 3.2 | Estimate consumption of antimicrobials used in the human sector annually, distribute the results to health care organizations and stakeholders, partners | + | + | + | + | Results on imported and locally produced antimicrobials | Consumption of antimicrobials will be estimated at the national level, compared with the Region | MMRA | MoH, WHO, research organisations |
| 3.3 | Conduct surveillance studies on healthcare-associated resistant bacteria in hospitals | - | + | ÷ | + | Surveillance reports | Conclusion and recommendations based on study results will be distributed to relevant authorities | NCCD | MMRA, Health organizations |
| 3.4 | Develop and get approval on list of prescription medicines and regulation on prescription in the veterinary sector | + | - | - | - | Regulation -1, List of drugs-1 | Regulation and list of drugs will approved, shared with public community | GAVS | Veterinary drug council |
| 3.5 | Develop a mapping tool for vetenary medicines on dispensing, use, disposal, monitoring and information and set-up database | - | + | + | + | Mapping, database | Annual data on antimicrobials and turnover will be produced. | GAVS | SLVMTC, GASI, Veterinary drug wholesalers, Veterinary pharmacy |

| 3.6 | Conduct assessment on use of antibiograms in hospitals to prescribe and select antibiotics in patient treatment | + | - | + | - | Number of assessed organizations | Recommendations and conclusions based on assessment will be distributed to relevant authorities. | MMRA | Health organizations |
|---------------------|---|--------|--------|--------|-------|--|---|------------------------------------|--|
| 3.7 | Require GMP for all local antimicrobial manufacturing, support to conduct continuous trainings | - | + | + | + | Number of local producers certified with GMP | Local manufacturers producing antimicrobials will be certified with GMP. | MMRA | Drug manufacturers, NGOs, associations |
| 3.8 | Include a requirement for bioequivalence test on multi- sourced generic antimicrobials to be registered in the country | + | + | + | + | Indication of the regulation/ clause order | Order will be approve | MMRA | Drug wholesalers |
| 3.9 | Conduct surveillance studies on hospital-level consumption of antimicrobial drugs | - | + | + | + | Number of surveillance studies | Conclusion and recommendations based on study results will be developed and distributed to relevant authorities | MMRA | Health organizations |
| 3.10 | Implement antimicrobial stewardship programs in health organizations, invite international consultant to conduct the trainings and share expertise | + | + | + | + | Number of health organizations | Central hospital and specialized centers will implement the AMS. | MMRA | Central hospitals, specialized hospitals |
| 3.11 | Take multi-sectoral joint measures to stop OTC availability of antimicrobials in community pharmacies | + | + | + | + | Number of controls and inspections o | All community pharmacies will sell antibiotics only per prescription. | MMRA, GAVS, Drug association | GASI |
| 3.12 | Conduct surveillance of antimicrobial residues in meat and milk | + | + | + | + | Surveillance report | Conclusion and recommendations based on study results will be developed and distributed to relevant authorities | GAVS | Research organizations, laboratories in aimag and city, SCVL |
| Strate infection | gic objective 4: Optimize infect | ion pr | eventi | on and | d con | trol, undertake preven | tive measures from environme | ntal contaminatio | n, stop the spread of |
| 4.1 | Organize capacity building trainings on AMR and IPC for health care workers | + | + | + | + | Number of trained health care staff | Trainings will be organized and knowledge and expertise of doctors will be improved | MoH, NCCD | Universities, MNUMS |

| 4.2 | Organise capacity building trainings on AMR and IPC for medicine and medical care inspectors | + | + | + | + | Number of trained inspectors | | MMRA, GAVS, GASI, GDHI | MoH, MNUMS, MoFALI, International organizations |
|------|---|---|---|---|---|---|--|---------------------------|--|
| 4.3. | Develop a guideline on the appropriate use of antimicrobials based on international standards and guidelines /One health/ | + | + | - | - | Number of international resources | Manual will be developed and distributed to veterinary organizations | MoFALI | МоН |
| 4.4 | Develop training and awareness raising materials on IPC for health care workers | + | + | - | - | Number of developed materials | Information materials will be distributed to health organizations | MoH, NCCD | International organizations |
| 4.5 | Organize evaluation and supportive supervisions on AMR and IPC in health care organizations | + | + | + | + | Number of organizations enrolled in assessment and monitoring | Recommendations based on assessment results will be distributed to relevant authorities | MoH, NCCD | Aimag, city health departments |
| 4.6 | Increase supply of sanitation and hygiene equipment and devices for soft goods in hospitals | + | + | + | + | Number of devices used sanitation and disinfection | Sanitation and disinfection of soft goods will be improved | Health organizations | - |
| 4.7 | Increase stock on linen and other goods for hospitalized patients | + | + | + | + | Stock of patient gowns, bed, soft goods | Patients will be provided required sheets, gowns from internal stock | Health organizations | - |
| 4.8 | Conduct surveillance study on hospital -acquired infections and pathogens | - | + | - | + | Surveillance report | Recommendations based on assessment results will be distributed to relevant authorities | NCCD | MNUMS, health departments |
| | egic objective 5: Raise awareness edge and practice to prevent and r | | | | | | mais, incorporate the training m | odules in high sch | iooi cumcula, improve |
| 5.1 | Conduct a KAP survey on rational use of antimicrobials and AMR among public | + | + | + | + | Number of planned activities | Planned activities will be implemented . | MMRA, GAVS | MoH, MoFALI, MoE, NCPH, research |

| | annually to develop and implement awareness raising and advocacy plan | | | | | | | | organizations, Public relations organizations |
|-----|--|---|---|---|---|---|---|---|---|
| 5.2 | Disseminate information thru media regarding AMR in human health and agriculture sectors according to the developed plan | + | + | + | + | Number of results | Community members knowledge will be improved | MMRA, GAVS | MoH, MoFALI, NGOs |
| 5.3 | Develop public communication strategy on AMR and use of antimicrobials | - | + | - | - | Communication strategy document will be developed and approved | Communication strategy will be distributed to relevant authorities. | International organizations, GAVS, MMRA | MoH, MoFALI |
| 5.4 | Organise World Antimicrobial Awareness Week every year | + | + | + | + | Number of activities, trainings | Activities and trainings will be completed in accordance with the working plan | MMRA, GAVS | MoH, MoFALI |
| 5.5 | Organise AMR campaigns during other world health days with emphasis of relevant issues | + | + | + | + | Program will include topics on AMR | Activities and trainings will be completed in accordance with the working plan | MMRA, GAVS, NCPH | International organizations |
| 5.6 | Organise one-month campaign at hospitals on rational use of antimicrobials every year | + | + | + | + | Number of health organisations implementing the campaign | Plans and agenda will be developed and distributed to health organizations. | MMRA | Health organizations |
| 5.7 | Capacity building on estimation of AMR economic burden | - | + | + | - | Number of healthcare staff | Knowledge of healthcare staff will be improved, enabling them to estimate the economic burden caused by AMR | MMRA, GAVS | GDHI, Higher education providers, selected hospitals |
| 5.8 | Conduct assessment on KAP on AMR among health and veterinary sector workers | - | + | + | - | Number of assessments | Recommendations based on assessment results will be distributed to relevant authorities | MMRA, GAVS | Health organizations |
| 5.9 | Develop training program for herders and agriculture workers on good practices related to appropriate use of antimicrobials to improve their knowledge and practice | + | + | - | - | Number of organized trainings | Trainings will be conducted in accordance to the working plan | MoFALI, GAVS, MULS | Education providers |

| 5.10 | Include modules on AMR and rationale use of antimicrobials in postgraduate training programs for veterinary professionals | - | + | + | - | Number of veterinary doctors receiving the credit hours | Module will be integrated in the training program, knowledge of veterinarians will be improved | MULS, MoES | GAVS, Higher education providers, NGOs |
|------|---|---|---|---|---|--|---|---------------------|--|
| 5.11 | Include AMR surveillance, laboratory detection methods in the laboratory programme of the field epidemiology training curriculum | - | + | + | - | Number of credit hours included in the program | Module will be integrated in the training program, knowledge of students will be improved | NCCD | MMRA |
| 5.12 | Organise trainings with credit hours on rational use, prescription policy and consequences of AMR for PHC (soum and family health) practitioners | + | + | + | + | Number of family group practitioners receiving credit hours | Knowledge of family group practitioners will be improved | MMRA, NCHD, AFGP | NCPH, Higher education providers |
| 5.13 | Develop a proposal to include rational use of antimicrobials, AMR consequences in the secondary school health programme and discuss | - | + | + | - | Number of activities to be included in the program | Recommendations will be developed and submitted to the MoES | MMRA, GAVS | MoES |
| 5.14 | Organize national and subnational trainings on AMR and rational use of antimicrobials with credits | - | + | + | + | Number of trainings | Trainings will be conducted in accordance to the working plan | GAVS | Education providers |